JP2025508820A - Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用 - Google Patents

Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用 Download PDF

Info

Publication number
JP2025508820A
JP2025508820A JP2024550131A JP2024550131A JP2025508820A JP 2025508820 A JP2025508820 A JP 2025508820A JP 2024550131 A JP2024550131 A JP 2024550131A JP 2024550131 A JP2024550131 A JP 2024550131A JP 2025508820 A JP2025508820 A JP 2025508820A
Authority
JP
Japan
Prior art keywords
acid
gglu
amino
valine
aib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508820A5 (https=
Inventor
ジャニャック，フィリップ
オゾー，マリー－ロール
ロベルシ，ダニエラ
ビアンキ，エリサベッタ
トリッペピ，マルティナ
サントプレーテ，アレッシア
Original Assignee
コルテリア ファーマシューティカルズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コルテリア ファーマシューティカルズ filed Critical コルテリア ファーマシューティカルズ
Publication of JP2025508820A publication Critical patent/JP2025508820A/ja
Publication of JP2025508820A5 publication Critical patent/JP2025508820A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2024550131A 2022-02-23 2023-02-21 Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用 Pending JP2025508820A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
EP22158188.7 2022-02-23
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (2)

Publication Number Publication Date
JP2025508820A true JP2025508820A (ja) 2025-04-10
JP2025508820A5 JP2025508820A5 (https=) 2025-12-23

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550131A Pending JP2025508820A (ja) 2022-02-23 2023-02-21 Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用

Country Status (15)

Country Link
US (1) US20260001928A1 (https=)
EP (2) EP4234574A1 (https=)
JP (1) JP2025508820A (https=)
KR (1) KR20240153565A (https=)
CN (1) CN118843638A (https=)
AU (1) AU2023224327A1 (https=)
CA (1) CA3247142A1 (https=)
ES (1) ES3063881T3 (https=)
HR (1) HRP20260115T1 (https=)
IL (1) IL314055A (https=)
IS (1) IS050770A (https=)
MX (1) MX2024010296A (https=)
PL (1) PL4482578T3 (https=)
WO (1) WO2023161229A1 (https=)
ZA (1) ZA202406196B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104264A1 (en) * 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US20250243255A1 (en) * 2020-08-19 2025-07-31 Sanofi Crf2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
KR20240153565A (ko) 2024-10-23
IS050770A (is) 2024-10-15
CN118843638A (zh) 2024-10-25
ZA202406196B (en) 2025-03-26
EP4482578C0 (en) 2025-12-24
ES3063881T3 (en) 2026-04-21
EP4482578B1 (en) 2025-12-24
EP4482578A1 (en) 2025-01-01
IL314055A (en) 2024-09-01
HRP20260115T1 (hr) 2026-03-13
EP4234574A1 (en) 2023-08-30
MX2024010296A (es) 2024-09-18
US20260001928A1 (en) 2026-01-01
WO2023161229A1 (en) 2023-08-31
AU2023224327A1 (en) 2024-08-29
PL4482578T3 (pl) 2026-03-16
CA3247142A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CN111491658B (zh) 肠促胰岛素类似物及其用途
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
JP7832927B2 (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
US8450266B2 (en) Analogues of glucose-dependent insulinotropic polypeptide
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
KR102755938B1 (ko) 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도
WO2005077094A9 (en) Pancreatic polypeptide family motifs and polypeptides comprising the same
CN102596228A (zh) 神经肽-2受体(y-2r)激动剂
WO2024163535A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
HK40095414A (en) Crf2 receptor agonists and their use in therapy
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
JP2026071260A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用
KR20260022948A (ko) Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
TW202511281A (zh) 抗病毒多肽類似物

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212